Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
02/04/2026
The total deposits of the Reserve Bank of India increased by 3.84% compared to the end of March.
Latest
4 m ago
Laisi Information won the bid for the provincial-level low-altitude flight comprehensive management service platform project in Liaoning Province.
4 m ago
State Grid's fixed asset investment in the first quarter was nearly 130 billion yuan.
5 m ago
The second quarter provincial major project construction work conference was held in Xuchang in 2026. Liu Ning attended and delivered a speech, while Wang Kai presided over the meeting.
7 m ago
A report jointly released by the United Nations, the African Union, and the African Development Bank pointed out that prolonging the duration of the Gulf War will cause a 0.2 percentage point decrease in Africa's GDP growth rate in 2026.
7 m ago
Chi Fei Biotech announced that the company signed a revised and restated supply, distribution, and co-promotion agreement with MSD on April 2, 2026. The original agreement will terminate upon the effectiveness of the new agreement. The new agreement aims to deepen the strategic cooperation between the two parties, enhance market synergy, address operational pressures, and includes products such as the nine-valent HPV vaccine. The cooperation period extends until the end of 2028 and may be extended for two years. The company will adjust procurement and supply quantities dynamically based on market demand, and performance under the agreement will be disclosed regularly. The new agreement no longer specifies a base purchase amount for the agreement products. Chi Fei Biotech and MSD will negotiate and confirm expected procurement and supply plans based on market expectations and actual vaccination situations. The company will then procure the agreement products on a rolling basis. Specific procurement details will be based on orders confirmed in writing by both parties.
See all latest
